1 Felts W, Yelin E. The economic impact of the rheumatic diseases in the United States. J Rheumatol. 1989;16(7):867–84.
2 Fitzcharles MA, Shir Y. Management of chronic pain in the rheumatic diseases with insights for the clinician. Ther Adv Musculoskelet Dis. 2011;3(4):179–90.
3 Silverstein FE, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. Jama. 2000;284(10):1247–55.
4 Watson DJ, et al. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med. 2000;160(19):2998–3003.
5 Schnitzer TJ, et al. A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis. Clin Rheumatol. 2011;30(11):1433–46.
6 Pillans PI, et al. Severe acute liver injury associated with lumiracoxib. J Gastroenterol Hepatol. 2012;27(6):1102–5.
7 Langton PE, Hankey GJ, Eikelboom JW. Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions: we need processes in place to follow up suspicions about serious adverse events. Med J Aust. 2004;181(10):524–5.
8 Bally M, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ. 2017;357:j1909.
9 Theiler R, Dudler J. Drug therapy of pain: reason overwhelmed by emotion? Rev Med Suisse. 2013;9(401):1846–53.
10 Andrade S, et al. Safety of metamizole: a systematic review of the literature. J Clin Pharm Ther. 2016;41(5):459–77.
11 Kotter T, et al. Metamizole-associated adverse events: a systematic review and meta-analysis. PLoS One. 2015;10(4):e0122918.
12 Knusel O. Analgetische Therapie mit Zomerpirac im Vergleich zu Metamizol bei Arthrosen. Therapiewoche. 1982;32:4933–8.
13 Geisslinger G, et al. The effects on platelet aggregation and prostanoid biosynthesis of two parenteral analgesics: ketorolac tromethamine and dipyrone. Thromb Haemost. 1996;76(4):592–7.
14 Lanas A, et al. Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs. Eur J Gastroenterol Hepatol. 2003;15(2):173–8.